IRIX

IRIDEX Corporation

$0.70

-1.74%
SectorHealthcareIndustryMedical DevicesCountryUnited States

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders.

Source: Yahoo Finance
AI summary

Price & performance

1M+20.3%
3M-15.2%
YTD-36.2%
1Y-26.1%
52-week range—
Beta0.91
Full chart and returns against a benchmark

Q-Score

44/ 100

Quality against peers; 50 is the peer median.

Growth35
Risk49
Performance34
Valuation59
Profitability56
Leverage45
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2026

Revenue$52.7M+8.2%
Net income-$4.4M
Net margin-8.4%+9.9 pts
Historical fundamentals

Red flags in filings

1active red flag
Exchange listing noticeSep 2, 2026
Filings, findings and the timeline

Revenue exposure

56%of revenue from outside the US
United States44%
Europe Middle East and Africa27%
Asia Pacific25%
Regions, segments, customers and suppliers

Valuation

IRIXIndustryP/E—29.61P/S0.243.49EV/EBITDA—18.38P/B3.383.39PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Nov 17next report, after the close
EPS estimate$-0.04
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate